Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
34537678
DOI
10.1016/j.jns.2021.118067
PII: S0022-510X(21)00763-2
Knihovny.cz E-zdroje
- Klíčová slova
- Clinically isolated syndrome, Expanded disability status scale (EDSS), MSBase registry, Optic neuritis, Vision,
- MeSH
- demyelinizační nemoci * MeSH
- dospělí MeSH
- kohortové studie MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- posuzování pracovní neschopnosti MeSH
- progrese nemoci MeSH
- registrace MeSH
- roztroušená skleróza * komplikace diagnóza epidemiologie MeSH
- zánět zrakového nervu * diagnóza epidemiologie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Short-term outcomes of optic neuritis (ON) have been well characterized. Limited data exists on longer-term visual outcomes in patients who present with ON. The large MSBase registry allows for characterization of long-term visual outcomes after ON. METHODS: Via the MSBase Registry, data on patients from 41 centers was collected during routine clinical and research visits. Physical and visual disability were measured using the expanded disability status scale (EDSS) and the visual function score (VFS). Inclusion criteria for this analysis included age ≥ 18 years, clinically isolated syndrome (CIS), ON-onset, baseline visit within 6 months of onset, and at least one follow-up visit. Survival analysis was used to evaluate the association of disease-modifying treatment with time to conversion to clinically definite MS or sustained EDSS/VFS progression. RESULTS: Data from 60,933 patients were obtained from the MSBase registry in July 2019. Of these, 1317 patients met inclusion criteria; 935 were treated at some point in disease course, while 382 were never treated. At baseline, mean age was 32.3 ± 8.8 years, 74% were female, median EDSS was 2 (IQR 1-2), and median VFS was 1 (IQR 0-2). Median follow-up time was 5.2 years (IQR 2.4-9.3). Treatment was associated with reduced risk and delayed conversion to clinically definite MS (HR = 0.70, p < 0.001), sustained EDSS progression (HR = 0.46, p < 0.0001) and sustained VFS (HR = 0.41, p < 0.001) progression. CONCLUSIONS: In the MSBase cohort, treatment after ON was associated with better visual and neurological outcomes compared to no treatment. These results support early treatment for patients presenting with ON as the first manifestation of MS.
A O S Giuseppe Moscati Avellino Italy
Amiri Hospital Kuwait City Kuwait
Azienda Sanitaria Unica Regionale Marche Ancona Province of Ancona Italy
Bakirkoy Hospital Of Mental Disorders And Neuro Bakirkoy Istanbul Turkey
Centro Internacional de Restauracion Neurologica La Habana Cuba
Charles University Prague and General University Hospital Prague Czech Republic
Cliniques Universitaires Saint Luc UCLouvain Brussels Belgium
Department of Medicine and Surgery University of Parma Italy
Department of Neurology New York University Grossman School of Medicine New York NY USA
Department of Population Health New York University Grossman School of Medicine New York NY USA
Dokuz eylul uni faculty of medicine Izmir Turkey
Haydarpasa Numune Training and Research Hospital Istanbul Turkey
Hospital Universitario Virgen Macarena Seville Spain
IRCCS Mondino Foundation Pavia Italy
Johns Hopkins University School of Medicine Baltimore MD USA
KTU Medical Faculty Farabi Hospital Trabzon Turkey
Monash University Melbourne Victoria Australia
MS Centre Royal Melbourne Hospital CORe Department of Medicine University of Melbourne Melbourne AU
Neurologicka Klinika 1 LF UK Prague Czech Republic
Neurologicka Klinika Jihlava Jihlava Czech Republic
Nuovo Ospedale Civile S Agostino Estense Baggiovara MO Italy
Ondokuz Mayis Universitesi Samsun Turkey
University G d'Annunzio Chieti Pescara Italy
University of Modena and Reggio Emilia Modena Province of Modena Italy
Citace poskytuje Crossref.org